open access

Vol 53, No 5 (2022)
Original research article
Submitted: 2022-05-27
Accepted: 2022-06-24
Published online: 2022-10-31
Get Citation

Use of convalescent plasma in patients with COVID-19

Katarzyna Gągola1, Jan Styczyński2
DOI: 10.5603/AHP.a2022.0044
·
Acta Haematol Pol 2022;53(5):335-344.
Affiliations
  1. Regional Center of Blood Donation and Blood Treatment, Bydgoszcz, Poland
  2. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University in Toruń, Jurasz University Hospital 1, Bydgoszcz, Poland

open access

Vol 53, No 5 (2022)
ORIGINAL RESEARCH ARTICLE
Submitted: 2022-05-27
Accepted: 2022-06-24
Published online: 2022-10-31

Abstract

Introducton: We wished to evaluate the clinical effectiveness of convalescent plasma (CP) in coronavirus disease 2019 (COVID-19) patients treated in hospitals in the Kuyavian-Pomeranian Voivodeship, including the impact of treatment duration and CP antibody titer on the course of hospitalization and patient survival in relation to other risk factors.

Material and methods: This was a retrospective analysis of clinical data of CP use in hospitals in the Kuyavian-Pomeranian Voivodeship.

Results: A total of 3,596 patients had available clinical data. In 59% of patients, CP was administered during the initial 24 hours of hospitalization (median: 1 day, range 1–49). In cured patients, hospital length of stay correlated with time of CP administration (p <0.001), i.e. the sooner the COVID-19 convalescent plasma (CCP) was administered, the shorter the hospitalization. Overall survival in analyzed COVID-19 patients was 78.3%, and it was better when CP was administered during the first day of hospitalization (79.9% vs. 86.8%, p = 0.057), in younger patients (91.0% vs. 76.2% for patients <50 years and older, respectively; p <0.001); in patients not requiring invasive ventilation (78.7% vs. 26.9%, p <0.001), in good performance status patients (92.5% vs. 81.0% and 68.6% in patients in moderate and poor performance status, respectively; p <0.001); and in patients without comorbidities (88.6% vs. 75.9%, p <0.001). In turn, blood group and titers of antibodies against severe acute respiratory syndrome coronavirus 2 in CP had no impact on survival. In multivariate analysis, the following factors increased the risk of death from COVID-19: general clinical status at admission (poor > moderate > good), comorbidities, mechanical ventilation required. Risk of death was decreased in younger patients (continuous variable), while administration of CP within the first day of hospitalization had borderline significance (p = 0.077). The use of CP was a safe therapeutic approach. Mild reactions were reported after just 5/9,356 (0.05%) transfusions.

Conclusions: The early administration of CP had a beneficial effect on the clinical course of treatment in COVID-19 patients.

Abstract

Introducton: We wished to evaluate the clinical effectiveness of convalescent plasma (CP) in coronavirus disease 2019 (COVID-19) patients treated in hospitals in the Kuyavian-Pomeranian Voivodeship, including the impact of treatment duration and CP antibody titer on the course of hospitalization and patient survival in relation to other risk factors.

Material and methods: This was a retrospective analysis of clinical data of CP use in hospitals in the Kuyavian-Pomeranian Voivodeship.

Results: A total of 3,596 patients had available clinical data. In 59% of patients, CP was administered during the initial 24 hours of hospitalization (median: 1 day, range 1–49). In cured patients, hospital length of stay correlated with time of CP administration (p <0.001), i.e. the sooner the COVID-19 convalescent plasma (CCP) was administered, the shorter the hospitalization. Overall survival in analyzed COVID-19 patients was 78.3%, and it was better when CP was administered during the first day of hospitalization (79.9% vs. 86.8%, p = 0.057), in younger patients (91.0% vs. 76.2% for patients <50 years and older, respectively; p <0.001); in patients not requiring invasive ventilation (78.7% vs. 26.9%, p <0.001), in good performance status patients (92.5% vs. 81.0% and 68.6% in patients in moderate and poor performance status, respectively; p <0.001); and in patients without comorbidities (88.6% vs. 75.9%, p <0.001). In turn, blood group and titers of antibodies against severe acute respiratory syndrome coronavirus 2 in CP had no impact on survival. In multivariate analysis, the following factors increased the risk of death from COVID-19: general clinical status at admission (poor > moderate > good), comorbidities, mechanical ventilation required. Risk of death was decreased in younger patients (continuous variable), while administration of CP within the first day of hospitalization had borderline significance (p = 0.077). The use of CP was a safe therapeutic approach. Mild reactions were reported after just 5/9,356 (0.05%) transfusions.

Conclusions: The early administration of CP had a beneficial effect on the clinical course of treatment in COVID-19 patients.

Get Citation

Keywords

convalescent plasma, COVID-19, SARS-CoV-2

Supp./Additional Files (1)
Strona tytułowa
Download
37KB
About this article
Title

Use of convalescent plasma in patients with COVID-19

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 5 (2022)

Article type

Original research article

Pages

335-344

Published online

2022-10-31

Page views

159

Article views/downloads

47

DOI

10.5603/AHP.a2022.0044

Bibliographic record

Acta Haematol Pol 2022;53(5):335-344.

Keywords

convalescent plasma
COVID-19
SARS-CoV-2

Authors

Katarzyna Gągola
Jan Styczyński

References (22)
  1. van Griensven J, Edwards T, Baize S, et al. Ebola-Tx Consortium. Efficacy of convalescent plasma in virelation to dose of Ebola rus antibodies. N Engl J Med. 2016; 375(23): 2307–2309.
  2. Wong VWS, Dai D, Wu AKL, et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003; 9(3): 199–201.
  3. Who Mers-Cov Research Group. State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr. 2013; 5.
  4. Hung IFn, To KKw, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4): 447–456.
  5. Styczyński J. Hematology and transfusion medicine facing COVID-19: perspectives beyond the pandemic. Acta Haematol Pol. 2020; 51(2): 58–59.
  6. Gągola K. Use of convalescent plasma in patients with COVID-19. Acta Haematol Pol. 2022; 53(5): 335–335.
  7. Dougan M, Nirula A, Azizad M, et al. BLAZE-1 Investigators. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021; 385(15): 1382–1392.
  8. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021; 325(7): 632–644.
  9. Dong Y, Mo Xi, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6).
  10. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021; 397(10289): 2049–2059.
  11. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021; 325(12): 1185–1195.
  12. Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020; 190(11): 2290–2303.
  13. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 2021; 384(11): 1015–1027.
  14. Libster R, Pérez Marc G, Wappner D, et al. Fundación INFANT–COVID-19 Group. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021; 384(7): 610–618.
  15. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. SIREN-C3PO Investigators. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med. 2021; 385(21): 1951–1960.
  16. Simonovich VA, Burgos Pratx LD, Scibona P, et al. PlasmAr Study Group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2021; 384(7): 619–629.
  17. Korley FK, Durkalski-Mauldin V, Callaway CW. Convalescent plasma for outpatients with COVID-19. Reply. N Engl J Med. 2021; 385(23): 2206–2207.
  18. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020; 136(20): 2290–2295.
  19. Betrains A, Godinas L, Woei-A-Jin FJ, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021; 192(6): 1100–1105.
  20. Thompson MA, Henderson JP, Shah PK, et al. COVID-19 and Cancer Consortium. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021; 61(8): 2503–2511.
  21. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021; 61(8): 2503–2511.
  22. Cohn CS, Estcourt L, Grossman BJ, et al. COVID-19 convalescent plasma: interim recommendations from the AABB. Transfusion. 2021; 61(4): 1313–1323.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via Medica Publishers

ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone +48 58 320 94 94, fax+48 58 320 94 60,

e-mail: journals@viamedica.pl